Grants for For Profit Organizations Other Than Small Businesses

The 2024-25 Physical and Digital Infrastructure Security Grant (DF) Program for Health Care Facilities, offered by the California Governor’s Office of Emergency Services (Cal OES), aims to enhance physical and digital security for healthcare facilities in California. This program aligns with the foundational mission of protecting vital health services and ensuring the safety of facilities that provide abortion-related and reproductive healthcare, which are often targets of violence and vandalism. The grant seeks to mitigate these threats, thereby supporting the continuity and accessibility of critical healthcare services across the state. The target beneficiaries of this grant are currently licensed community health centers, tribal health programs, non-profit hospitals not part of large health systems, and non-profit organizations whose membership includes such licensed facilities. All eligible applicants must be located in California and provide abortion-related services (or referrals) and reproductive healthcare services. The impact goal is to strengthen the security infrastructure of these facilities, creating safer environments for both patients and staff, and ensuring uninterrupted access to essential healthcare. The program's priorities and focuses include providing funding for physical facility enhancements, such as improved security measures for buildings, and digital security enhancements to protect against cyber threats and data breaches. The grant specifically targets facilities that may be vulnerable to violence and vandalism due to the nature of the services they provide. The funding aims to directly address these vulnerabilities, thereby safeguarding the operational capacity of these crucial healthcare providers. Expected outcomes and measurable results include a demonstrable improvement in the physical and digital security posture of funded facilities. This could involve a reduction in incidents of vandalism or violence, enhanced data protection, and increased patient and staff safety. The grant period is from September 1, 2024, through December 31, 2026, during which time facilities are expected to implement and integrate these security upgrades. Applicants can request up to $750,000 from the total available funding of $7,798,822. While specific "Foundation's strategic priorities and theory of change" are not explicitly detailed for Cal OES in the provided text, the underlying theory of change for this grant program appears to be that by providing targeted funding for security enhancements, the state can directly reduce risks to essential healthcare infrastructure. This proactive investment is expected to lead to greater resilience for healthcare facilities, particularly those offering sensitive services, thereby upholding public health and safety and ensuring that all Californians have access to necessary medical care without fear or disruption.

The FY24 PCRP Implementation Science Award supports studies that are expected to bridge the gap between research, practice, and policy through establishment of a knowledge base of interventions, clinical practices/guidelines, tools, and policies that can be deployed to targeted populations at the appropriate time and point of need. For the purposes of this funding opportunity, an implementation science study accesses strategies used and develops tools to enhance the systematic uptake of evidence-based health interventions into clinical and/or community settings in order to improve patient outreach, patient outcomes, and/or the effectiveness of health care.Impact: Research supported by the Implementation Science Award is expected to have the potential for major, near-term impact that will accelerate the widespread adoption of evidence-based practices in prostate cancer care, prevention, and survivorship. Applications are expected to identify the prostate cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Applications must also include a detailed research transition plan that articulates the pathway to moving the projects findings to the next phase for widespread clinical impact after successful completion of the award. Research transition plans are encouraged to consider future strategies targeting the patient, physician/provider, community, and/or healthcare system levels as applicable.Community Engagement: Applications are required to include members of the targeted population and/or community in the development and execution of the research project where appropriate. The research team must include one or more prostate cancer consumer advocate(s) or member(s) of the community, who will be integral throughout the planning and performance of the research project. Consumer advocates and/or community-based members should be involved in the development of the research question, project design, oversight, recruitment, and evaluation and dissemination of outcomes, as well as other significant aspects of the proposed project. Interactions with other team members should be well integrated and ongoing, not limited to attending seminars and semi-annual meetings; communication between the research team and the community should be frequent and bidirectional. The consumer advocates can be individuals who have been diagnosed with prostate cancer, a direct caregiver for someone who has been diagnosed with prostate cancer, or other representatives from the targeted community who are positioned to effect change. The consumer advocates and/or community-based members should have a high level of knowledge of current prostate cancer issues and the appropriate background in prostate cancer research and/or clinical care to contribute to the project or be otherwise positioned within the target community to effect changes in behavior based on projected outcomes. A list of implementation science resources and community or advocacy organizations is provided at the end of the Implementation Science Award Information section.Health Equity and Disproportionately Affected Populations: Regardless of the FY24 PCRP Overarching Challenge(s) being addressed, all research projects are strongly encouraged to consider health equity (e.g., access to evidence-based care) and/or have a focus on addressing the needs of disproportionately affected populations in the application.Research Scope: The Implementation Science Award mechanism is intended to fund studies including, but not limited to, the following: Small-scale clinical trials (up to phase 2) that contain clear reporting and implementation strategies to narrow the research-to-practice timeline and improve care for prostate cancer survivors, particularly within disproportionately affected populations Interventions that focus on behavioral or lifestyle changes at the patient, provider, community, and/or policy level Comparative effectiveness research establishing the benefits and harms of emerging or standard-of-care interventions and strategies to prevent, diagnose, treat, and monitor health conditions in real-world settings Development and evaluation of strategies to overcome barriers to health care access across the cancer care continuum Altering the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines.Preliminary data to support the scientific rationale and feasibility of the research approaches are required. These preliminary data do not need to have been generated solely in prostate cancer. The inclusion of additional preliminary data to support the clinical relevance of the idea is strongly encouraged.Investigators proposing a clinical trial are highly encouraged to consider leveraging the PCRP Prostate Cancer Clinical Trials Consortium (https://pcctc.org) to facilitate the rapid initiation and completion of the trial.Correlative studies that are associated with ongoing clinical trials, and preclinical studies involving the use of animals do not meet the intent of the FY24 PCRP Implementation Science Award.Partnering Principal Investigator (PI) Option: The FY24 PCRP Implementation Science Award encourages applications that include meaningful and productive collaborations between two investigators. The PIs may have expertise in similar or disparate scientific and/or clinical disciplines, but each PI is expected to bring distinct contributions to the application. The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development and execution of the proposed research project. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PIs, refer to Section II.D.2, Content and Form of the Application Submission.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP prioritiesInnovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.A Clinical Trial Option allows for studies proposing small-scale clinical trials with a focus on implementation science. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Applications proposing a clinical trial are expected to provide detailed plans for initiating the clinical study within the first year, including U.S. Food and Drug Administration (FDA) Investigational New Drug/Investigational Device Exemption application submission plans, within 60 days of the award.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.Implementation Sciences Resources: Potential applicants for this award are encouraged to seek collaborations and access to appropriate study populations through the following (or similar) resources: CDMRP: Search the CDMRP awards database at https://cdmrp.health.mil. The North Carolina Louisiana Prostate Cancer Project (PCaP): The PCaP was supported by the PCRP to conduct prostate cancer health disparity studies and developed a large biorepository of health disparity-related epidemiological data and biospecimens that may be requested for use by the research community. Information on PCaP investigators, data, and specimens is available at https://pcap.bioinf.unc.edu. National Cancer Institute Center to Reduce Cancer Health Disparities: Search for health disparity research and researchers at https://crchd.cancer.gov/index.html. National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH), Community-Based Participatory Research (CBPR) Initiative: Contact the NIMHD at https://www.nimhd.nih.gov/programs/extramural/community-based-participatory.html for information on current CBPR programs and scientists and communities engaged in health disparity research. Cancer Prevention and Control Research Network (CPCRN): Contact the CPCRN at https://cpcrn.org/ for information on community participatory research to reduce cancer in disproportionately affected populations. Health Resources and Services Administration, Office of Minority Health: Search for health disparity programs and funded investigators at https://www.hrsa.gov/index.html. NIH Research Portfolio Online Reporting Tool (NIH RePORTER): Search for NIH awards at https://projectreporter.nih.gov/reporter.cfm. Defense Technical Information Center (DTIC): Search for Department of Defense (DOD) and other government-funded investigators through DTIC Technical Reports at https://discover.dtic.mil/. National Library of Medicine, NIH, PubMed: Search for investigators publishing studies on prostate cancer health disparities at https://www.ncbi.nlm.nih.gov/pubmed. U.S. Department of Education: Search for institutions that may have increased access to disproportionately affected populations at https://www2.ed.gov/about/offices/list/ocr/edlite-minorityinst.html. International Cancer Research Partnership: Search for investigators and studies relevant to health disparity that are supported by cancer research funders from several countries including the United States, European Union, United Kingdom, and Canada at https://www.icrpartnership.org. National Coalition for LGBT Health: For more information on programs focused on Lesbian, Gay, Bisexual, and Transgender (LGBT) research, policy, education, and training, search https://www.healthlgbt.org. National LGBT Cancer Network: To obtain more information, search https://www.cancer-network.org.In addition, the following is a list of potential community and/or advocacy organizations that applicants may find helpful to satisfy the requirement for community engagement within their proposed studies: the American Indian Health Care Association, National African American Outreach Program of the Patient Advocate Foundation, National Alliance for Hispanic Health, National Medical Association, National Rural Health Association, and Prostate Health Education Network, as well as international organizations such as the African-Caribbean Cancer Consortium, African Organization for Research and Training in Cancer, Europa Uomo, European Cancer Patient Coalition, Global Prostate Cancer Alliance, Malecare, Men of African Descent and Carcinoma of the Prostate Consortium, Prostate Cancer Transatlantic Consortium, Urban League, and The Prostate Net.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 PCRP Implementation Science Award should not exceed $2.0M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $9.6M to fund approximately three PCRP Implementation Science Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This program to build social cohesion between at-risk groups in northern Ghana and northern Cote dIvoire by improving equitable access to livelihoods in communities hosting refugees and asylum seekers in these regions. Impoverished host communities demonstrate resentment and hostility towards growing refugee/asylum seeker populations in this region as they compete for land, resources, and support from the state and from nongovernmental organizations. Through strengthening inclusive, equitable, and sustainable communal management of land and water resources in communities hosting refugees/asylum seekers, increasing equitable economic exchange between host communities and refugees/asylum seekers, and building conflict management skills in these communities, this program will improve equitable access to livelihoods for at-risk communities, thereby contributing to strengthened social cohesion between these groups in keeping with Objective 1 of the 10-Year Plan to implement the Strategy to Prevent Conflict and Promote Stability in Coastal West Africa.

The PRP EIRA supports research opportunities for investigators in the early stages of their careers. The Early Investigator is considered the Principal Investigator (PI) of the application and must exhibit strong potential for, and commitment to, pursuing a career as an investigator at the forefront of PD research; however, the PI is not required to have previous PD research experience.

This program provides $5,000 to eligible Worcester-based businesses seeking certifications as Minority-Owned, Women-Owned, or Veteran-Owned through the Massachusetts Supplier Diversity Office.

The Fund Her Future grant program, administered by Block Advisors by H&R Block, offers a total of $100,000 in grants to support the growth of women-owned businesses. This initiative aims to address the funding disparities faced by women, one of the fastest-growing segments of new small business owners. One grand prize winner will receive $50,000, with additional finalists receiving $12,500 each. Alongside monetary awards, winners will also benefit from professional services including small business taxes, bookkeeping, payroll, and business structure analysis. Applications are accepted until May 26, 2024.

The FY24 DMDRP CTRA mechanism supports advanced translational research that will accelerate the movement of promising ideas in DMD research into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. However, applicants should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between applied and clinical research. As such, applications must include preliminary and/or published data relevant to DMD to support the proposed research project.This mechanism is intended to support established projects that have moved beyond the realm of basic research and proof of concept studies and have the potential to result in a near-term impact in clinical research or the clinic. Research projects investigating therapies that will be efficacious across the life span, including infants, toddlers, and non-ambulatory individuals, are strongly encouraged. Pilot, proof-of-principle clinical trials, and correlative studies to better inform development of drugs, devices, and other interventions are allowed.Early-Career Partnering PI Option: The FY24 DMDRP encourages applications that include meaningful and productive collaborations between investigators. In an effort to promote enhanced research capacity within the DMD field, the FY24 CTRA includes an option for an Early-Career Partnering Principal Investigator (PI). The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The Early-Career PI will be identified as the Partnering PI. Both PIs should contribute significantly to the development and execution of the proposed research project. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI, refer to Section II.D.2, Content and Form of the Application Submission.The FY24 DMDRP CTRA offers two funding levels (refer to Section II.D.5 Funding Restrictions). Only one funding level category may be chosen per application, and the choice of application category is at the discretion of the applicant. The following are generalized descriptions of the scope of the research appropriate for each funding level:Funding Level 1: Funding Level 1 is intended to support smaller, less complex preclinical and/or clinical research. Pilot clinical trials are allowed. The proposal/applications direct costs budgeted for the entire period of performance should not exceed $650,000.Funding Level 2: Funding Level 2 is intended to support larger, more complex preclinical and/or clinical research. Pilot clinical trials are allowed. The proposal/applications direct costs budgeted for the entire period of performance should not exceed $1.35M.Additionally, both funding levels will support an Early-Career Partnering PI Option at the same maximum direct costs and periods of performance, respectively.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Both pilot clinical trials and clinical research are permitted under this mechanism.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.All investigators applying to FY24 DMDRP funding opportunities and conducting clinical research are encouraged to consult the Strategies to Promote Diversity in Muscular Dystrophy Research Participation developed by the MDCC.

The FY24 DMDRP IDA promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with DMD. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale.New Investigators: The FY24 DMDRP IDA mechanism encourages applications from independent investigators in the early stages of their careers (i.e., within 10 years of their first faculty appointment or equivalent) or applications from established investigators new to DMD research.The New Investigator Early Stage category is designed to allow applicants early in their faculty appointments to compete for funding separately from established investigators.The New Investigator Transitioning category is designed to allow investigators in an area other than muscular dystrophy, at or above the level of Assistant Professor, seeking to transition to a career in DMD, thereby bringing their expertise to the field.Applications from New Investigators and Established Investigators will be peer and programmatically reviewed separately. Principal Investigators (PIs) using the New Investigator Early Stage category or New Investigator Transitioning category are strongly encouraged to strengthen their applications by collaborating with investigators experienced in DMD research and/or possessing other relevant expertise. It is the responsibility of the applicant to describe how the included collaboration will augment the PIs expertise to best address the research question. All applicants for the New Investigator categories must meet the specific eligibility criteria described in Section II.C, Eligibility Information.Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required. Preliminary data may include unpublished results from the laboratory of the PI, research team or collaborators named on the application.Key elements of this award are as follows:Innovation: Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities.Impact: Research that has high potential impact may lead to major advancements and significantly accelerate progress toward improving outcomes for individuals with DMD.It is the responsibility of the PI to clearly and explicitly articulate the projects innovation and its potential impact on DMD. The projects impact to both DMD research and to individuals with DMD should be articulated, even if clinical impact is not an immediate outcome. Applications that demonstrate exceptional scientific merit but lack innovation and high potential impact do not meet the intent of the IDA.Clinical trials are not allowed under this funding opportunity.A clinical trial is defined in 45 CFR 46.102 as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.

The PRP IIRA supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinsons research. This award mechanism supports the full spectrum of research from basic science through clinical research.

With this solicitation, OVC seeks to award a 36-month cooperative agreement to one lead organization that will (1) fund (through a competitive process) subawards to communities severely affected by violence to establish trauma recovery centers , and (2) provide technical assistance to the subawardees to support operation of the centers. The trauma recovery centers funded under this demonstration project will address crime victimization and support access to victims compensation, crime victims rights enforcement, trauma recovery, and healing. Subawardees will be expected to design centers to provide services to crime victims who traditionally do not seek victims services, assistance, or counseling, or are historically underserved. This demonstration is intended to span 5 years (60 months total) via an initial 3-year budget allocation under this solicitation, with the potential for noncompetitive continuation funding as the project moves from year 3 to year 5 of its implementation.

This NOFO seeks proposals from eligible applicants for activities to establish and operate a CHIPS Manufacturing USA Institute focused on digital twins with integrated physical assets and computational capabilities (digital assets) to tackle important semiconductor-industry manufacturing challenges. The CHIPS Manufacturing USA Institute will join an existing network of seventeen Institutes designed to increase U.S. manufacturing competitiveness and promote a robust R infrastructure. The Institute will manage a portfolio of Institute-led projects and competitively funded Member-led projects, including Education and Workforce Development (EWD) activities, basic and applied research, and technology demonstrations.

This grant provides financial support to non-profit organizations serving Linn County, Iowa, to develop innovative programs or sustain ongoing initiatives that benefit the community.

The Make it Minnesota Marketing Investment Cost-Share Program, funded by the Minnesota Department of Agriculture's AGRI Program, supports Minnesota-based consumer packaged goods (CPG) companies in food, beverage, or pet food sectors. The program reimburses 50% of eligible marketing investments up to a maximum of $3,000 per company per fiscal year. This funding can be used for in-store demonstrations, Minnesota Pavilion events, and B2B tradeshow costs, among other high-impact marketing activities. The program aims to help these companies increase their market presence both domestically and internationally.

This track of the Resilient Food Systems Infrastructure (RFSI) program provides approximately $1 million for grants aimed at purchasing equipment necessary for the middle of the food supply chain activities in Vermont. The grants range from $30,000 to $100,000 with no match requirement. Applications for this track are set to open in late August 2024 and close in early October 2024, with grant activities beginning in early 2025.

The Resilient Food Systems Infrastructure (RFSI) program, funded by the USDA, allocates approximately $2 million for infrastructure grants to Vermont businesses and organizations aiming to strengthen local and regional food systems. The grants support projects that improve the aggregation, distribution, manufacturing, processing, storing, transporting, and wholesaling of Vermont food products. This track encourages development of Vermont value-added products and promotes fair wages and job creation. A 50% match is required, which can be reduced to 25% for historically underserved farmers. Grants range from $100,000 to $500,000 and are available from fall 2024 through February 2027.

The Minnesota Pollution Control Agency (MPCA) invites proposals for a community air monitoring pilot grant program, targeting neighborhood-scale air quality monitoring in the Twin Cities metro area. Eligible organizations, primarily community nonprofits and their partners, will develop a dense network of fixed and mobile air sensors. Priority will be given to projects in environmental justice communities with robust community engagement. The objectives include monitoring air quality, fostering community cooperation, and providing actionable air quality data to MPCA. The application deadline is 4:30 p.m. Central Time on June 28, 2024.

The Goshen County Tourism Promotion Joint Powers Board [a.k.a. Goshen County Lodging Tax Board] is dedicated to enhancing travel and tourism across Goshen County. The board's initiatives focus on creating effective marketing strategies to promote the area as a travel destination. They have set aside approximately $321,000.00 for the Tourism Sponsorship Program, which grants funds to event organizers. These events are aimed at promoting local, regional, and national public relations efforts that bring both visitors and residents to Goshen County. Applicants need to demonstrate that their events can attract tourists and support the local tourism sector. The funding is reimbursed based on actual expenses reported after the event. Applications are due one the first Tuesday of January, April, July and October

9th Round of Child Care Workforce Stabilization Grant (CCWS) The Department of Human Resources is pleased to announce the 9th round of the Child Care Workforce Stabilization Grant (CCWS). These grants have been issued to child care providers since the onset of the Covid-19 Pandemic in March 2020, aiming to stabilize the child care community. The CCWS grants have significantly contributed to supporting recruitment and retention efforts in the sector. Grant Details: Grant Type: CCWS Grant Grant Amount: Bonus payment up to $3,000 to eligible child care staff Purpose: Staff retention and recruitment support Eligibility Requirements: Specific eligibility requirements outlined in the grant guidance accessible at https://dhr.alabama.gov/child-care/ Application period: April 17, 2024, to May 22, 2024 No late applications will be accepted All eligible providers must complete the initial application for this round

CSO announces an open competition for organizations interested in submitting applications for programs that support increasing the capacity of a cohort of civil servants within the Republic of Yemen Government (ROYG) to identify priorities for the development of inclusive stabilization plans.

Through this NOFO, HUD is announcing the availability of approximately $91,000,000 in total funding including $88,500,000 in FY 2024 funding for its Community Compass Technical Assistance and Capacity Building Program (Community Compass) and up to $2,500,000 in FY 2023 Departmental Technical Assistance funding for the Thriving Communities Technical Assistance program (TCTA). We reserve the right to award FY 2025 Community Compass funds based on this single NOFO competition.Community Compass is HUDs integrated technical assistance (TA) and capacity building initiative. Community Compass helps customers navigate complex housing and community development challenges. It equips them with knowledge, skills, tools, and capacity to implement HUDs programs and policies. Community Compass provides effective administrative and managerial oversight of HUD funding. Community Compass is centrally managed by HUD Headquarters with the involvement of our Regional, Field, and Area Offices.HUD's TCTA program helps local governments address pressing housing needs by identifying land for housing development near transportation projects; developing preservation and anti-displacement strategies; identifying and implementing reforms to reduce barriers to location-efficient housing; and improving coordination and supporting a holistic approach to housing and transportation.We recognize that our customers often interact with a variety of HUD programs, and other federal programs servicing common customers, as they deliver housing or community development services. Community Compass brings together TA investments from across HUD program offices, including the offices of Community Planning and Development, Fair Housing and Equal Opportunity, Housing, and Public and Indian Housing. This cross-funding approach allows TA to address the needs of grantees and subgrantees, often within the same engagement, and promotes intra- and inter-agency issue resolution. You are encouraged to procure contractors and consultants that demonstrate experience across a wide variety of HUD programs, as well as in specific skill and policy areas related to HUD programs. Through this NOFO, HUD will also address the TA needs of some emerging priorities that include: community violence intervention, implementation of and compliance with the Violence Against Women Act's (VAWA) 2022 Reauthorization, climate resilience, housing needs of youth, and environmental reviews. It is highly encouraged that applicants assemble a diverse team of professionals and people with lived experience from the communities HUD serves. Their perspectives can add immeasurable value in the development and delivery of technical assistance.